Company Description
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries.
It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS).
The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company’s BASi product line.
The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts.
The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services.
The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021.
Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
| Country | United States |
| Founded | 1974 |
| IPO Date | Nov 24, 1997 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 2,055 |
| CEO | Robert Leasure |
Contact Details
Address: 2701 Kent Avenue West Lafayette, Indiana 47906 United States | |
| Phone | 765 463 4527 |
| Website | inotivco.com |
Stock Details
| Ticker Symbol | NOTV |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0000720154 |
| CUSIP Number | 45783Q100 |
| ISIN Number | US45783Q1004 |
| Employer ID | 35-1345024 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Robert W. Leasure Jr. | President, Chief Executive Officer and Director |
| Beth A. Taylor CPA | Senior Vice President of Finance and Chief Financial Officer |
| Dr. John E. Sagartz D.V.M., DiplomateACVP, Ph.D. | Chief Strategy Officer and Director |
| Dr. Peter T. Kissinger | Founder, Chairman Emeritus and Scientific Advisor |
| Brennan Freeman | Vice President of Finance, Principal Accounting Officer and Corporate Controller |
| Andrea Castetter | SVice President of General Counsel, Corporate Secretary and Chief Compliance Officer |
| Jeffrey Arthur Krupp | Chief Human Resources Officer |
| John Gregory Beattie DSA | Chief Operating Officer of DSA |
| Dr. Adrian Hardy Ph.D. | Chief Commercial Officer |
| Lizanne Muller | Group President of RMS |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 15, 2024 | EFFECT | Notice of Effectiveness |
| Oct 3, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Sep 19, 2024 | 8-K | Current Report |
| Aug 9, 2024 | 8-K | Current Report |
| Aug 9, 2024 | 424B5 | Filing |
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Jun 4, 2024 | 8-K | Current Report |
| May 24, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 24, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |